Jump to content

Pipendoxifene

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Entranced98 (talk | contribs) at 00:07, 23 January 2023 (Importing Wikidata short description: "Chemical compound"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pipendoxifene
Clinical data
Other namesERA-923
Identifiers
  • 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H32N2O3
Molar mass456.586 g·mol−1
3D model (JSmol)
  • CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
  • InChI=1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3
  • Key:JICOGKJOQXTAIP-UHFFFAOYSA-N

Pipendoxifene (INN) (developmental code name ERA-923) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development by Ligand Pharmaceuticals and Wyeth-Ayerst Laboratories (now Wyeth) for the treatment of breast cancer but was not marketed.[1][2][3] It is a member of the 2-phenylindole group of SERMs and is structurally related to zindoxifene and the marketed bazedoxifene.[2][3] The drug reached phase II clinical trials before its development was discontinued.[1][2] It was synthesized at the same time as bazedoxifene and was intended as a backup drug for bazedoxifene, only to be developed further if bazedoxifene had failed in clinical trials.[1][2] No further development was reported after 2002 and it was formally announced that development had been terminated in November 2005.[1][4]

Unlike the SERM raloxifene, pipendoxifene is devoid of uterotrophic activity in immature/ovariectomized rodents.[3][5]

References

  1. ^ a b c d "Pipendoxifene". Addis Insight. Springer Nature Switzerland AG.
  2. ^ a b c d Gribble GW (9 October 2010). Heterocyclic Scaffolds II:: Reactions and Applications of Indoles. Springer Science & Business Media. pp. 14–. ISBN 978-3-642-15732-5.
  3. ^ a b c Prudhomme M (14 June 2013). Advances in Anticancer Agents in Medicinal Chemistry. Bentham Science Publishers. pp. 368–369. ISBN 978-1-60805-496-1.
  4. ^ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 95–. ISBN 978-3-527-62330-3.
  5. ^ Cano A, Calaf i Alsina J, Duenas-Diez JL (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 58–. ISBN 978-3-540-34742-2.



Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pipendoxifene&oldid=1135157414"